Prostate-specific antigen (PSA) testing of men in UK general practice: A 10-year longitudinal cohort study

BMJ Open

Volumn 7, Issue 10, 2017, Pages

  Young, Grace J ^a   Harrison, Sean ^a   Turner, Emma L ^a   Walsh, Eleanor I ^a   Oliver, Steven E ^b   Ben Shlomo, Yoav ^a   Evans, Simon ^c   Lane, J Athene ^a   Neal, David E ^d   Hamdy, Freddie C ^d   Donovan, Jenny L ^a   Martin, Richard M ^a   Metcalfe, Chris ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c ROYAL UNITED HOSPITAL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Primary health care; Prostate cancer; PSA testing; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; FOLLOW UP; GENERAL PRACTICE; GROUPS BY AGE; HUMAN; LONGITUDINAL STUDY; LOWER URINARY TRACT SYMPTOM; MALE; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; UNITED KINGDOM; AGE; BIOPSY; BLOOD; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; EARLY CANCER DIAGNOSIS; MASS SCREENING; MEN'S HEALTH; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; URINARY TRACT DISEASE;

AGE FACTORS; AGED; BIOPSY; COHORT STUDIES; CROSS-SECTIONAL STUDIES; EARLY DETECTION OF CANCER; FAMILY PRACTICE; GENERAL PRACTICE; HUMANS; LONGITUDINAL STUDIES; MALE; MASS SCREENING; MEN'S HEALTH; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UROLOGIC DISEASES;

EID: 85032656717     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2017-017729     Document Type: Article

References (29)

1. Office for National Statistics [ONS]. Cancer Registration Statistics, England. 2015 https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/2015 (accessed 7 July 2017).
2. Roobol MJ. The prostate-specific antigen test. Expert Opin Med Diagn 2013;7:423-6.
3. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027-35.
4. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762-U94.
5. Gulati R, Mariotto AB, Chen S, et al. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol 2011;64:1412-7.
6. Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016;375:1425-37.
7. Pickles K, Carter SM, Rychetnik L. Doctors' approaches to PSA testing and overdiagnosis in primary healthcare: a qualitative study. BMJ Open 2015;5:e006367.
8. Melia J, Moss S, Johns L. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 2004;94:51-6.
9. Williams N, Hughes LJ, Turner EL, et al. Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. BJU Int 2011;108:1402-8.
10. Moss S, Melia J, Sutton J, et al. Prostate-specific antigen testing rates and referral patterns from general practice data in England. Int J Clin Pract 2016;70:312-8.
11. Nderitu P, Van Hemelrijck M, Ashworth M, et al. Prostate-specific antigen testing in inner London general practices: are those at higher risk most likely to get tested? BMJ Open 2016;6:e011356.
12. Roehrborn CG, McConnell JD, Lieber M, et al. Serum prostatespecific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999;53:473-80.
13. National Institute of Health and Care Excellence [NICE]. National Institute for Health and Care Excellence: Clinical Guidelines, 2015. https://cks. nice.org.uk/luts-in-men#!topicsummary. (accessed 14 Mar 2017).
14. National Institute for Health and Care Excellence [NICE]. Lower urinary tract symptoms in men: management, 2010. https://www.nice.org.uk/guidance/cg97/chapter/1-Recommendations. (accessed 14 Mar 2017).
15. Nordstrom T, Aly M, Clements MS, et al. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol 2013;63:419-25.
16. Hamoen EH, Reukers DF, Numans ME, et al. Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing. Fam Pract 2013;30:648-54.
17. Lane JA, Donovan JL, Davis M, et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 2014;15:1109-18.
18. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997;350:1097-9.
19. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827-36.
20. Campbell J, Dedman DJ, Eaton SC, et al. Is the CPRD GOLD Population Comparable to the UK Population? Pharmacoepidemiology and Drug Safety 2013;22:280-1.
21. Collin SM, Metcalfe C, Donovan J, et al. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screendetected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. BJU Int 2008;27:583-84.
22. Andersson SO, Rashidkhani B, Karlberg L, et al. Prevalence of lower urinary tract symptoms in men aged 45-79 years: a population-based study of 40 000 Swedish men. BJU Int 2004;94:327-31.
23. Young JM, Muscatello DJ, Ward JE. Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Int 2000;85:1037-48.
24. Martin RM, Vatten L, Gunnell D, et al. Lower urinary tract symptoms and risk of prostate cancer: the HUNT 2 Cohort, Norway. Int J Cancer 2008;123:1924-8.
25. Speakman MJ, Kirby RS, Joyce A, et al. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 2004;93:985-90.
26. The National Cancer Registration and Analysis Service. Cancer by Deprivation in England 1996-2011. 2014 http://www.ncin.org.uk/about-ncin/cancer-by-deprivation-in-england (accessed 14 Mar 2017).
27. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostatecancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
28. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310-9.
29. Collin SM, Metcalfe C, Donovan J, et al. Associations of sexual dysfunction with localized and advanced prostate cancer: a case-control study nested within the Uk population-based protect (Prostate Testing for Cancer and Treatment) study. European Urology Supplements 2009;8:139-39.